Hans Hammers/utswmed.org
Mar 28, 2025, 10:31
Hans Hammers: The Werewolf Therapeutics trial with WTX-124 has opened
Hans Hammers, Professor at UT Southwestern Medical Center, posted on X:
“Excited to announce that the Werewolf Therapeutics trial with WTX-124 has opened. Intriguing way to deliver effective IL-2 without hospitalizations or ICU.
Single agent activity. If you have Kidney Cancer, Lung Cancer or Melanoma / Skin cancer then get in touch!”
Tian Zhang, Associate Director of Clinical Research at Simmons Comprehensive Cancer Center and Director of Clinical Research at UT Southwestern Medical Center, shared this post on X, adding:
“Glad to have this trial speed thru activation! Enrollment is ongoing!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 14:56
Apr 20, 2025, 14:07
Apr 20, 2025, 13:49
Apr 20, 2025, 13:31